TOP 100 WEIGHT LOSS SITES
| |||
|
| |||
| |||
|
| |||
| Continued Damage From Banned Obesity Drug Revealed By Study Fenfluramine, the appetite suppressant drug banned in the US in 1997 due to fears over its links to heart conditions, has been shown to have serious long-term effects. In a report published in the open access journal BMC Medicine, researchers have shown that people who stopped using fenfluramine eleven years ago had damaged heart valves up to seven years later. medicalnewstoday.com |
"Obesity Problems Begin Before Conception" Government anti-obesity campaigns should be focussing on women of child-bearing age, say leading clinicians. Presidents of the Royal Society of Medicine's Sections of Obstetrics & Gynaecology, Endocrinology & Diabetes and Maternity & the Newborn, believe the government should be funding campaigns to target women of child-bearing age. medicalnewstoday.com |
Obesity Charity Launches First Awareness Week The country's pre-eminent obesity charity, the National Obesity Forum is staging its first consumer awareness week in November this year. National Obesity Week, (NOW!)is an initiative to raise awareness of personal weight status. While the obesity epidemic increases, research* has highlighted that nearly half of adults have an inaccurate picture of their own weight. medicalnewstoday.com |
10 And 11-Year Olds Feel Pressure To Have A Perfect Body, Canada A study of 4254 Canadian schoolchildren has shown a direct association between BMI and satisfaction with their body shape. The research, published in the open access journal BMC Public Health, shows a linear response for girls, who were happiest when thinnest, and a U-shaped response for boys, who were unhappy when they were too skinny or too fat. medicalnewstoday.com |
Hemodynamic Therapeutics Announces Successful Completion Of Initial Phase 2 Clinical Study For Novel Combination Hypertension Therapy Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound ("HTI-101"), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension... medicalnewstoday.com |